Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in Breast Cancer

March 9th 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies being investigated with CDK4/6 inhibitors in breast cancer.

Promising Debut for PARP Inhibitors Spurs Excitement for Future Therapy

March 9th 2019

The introduction of PARP inhibitors into the breast cancer treatment paradigm is a clinically meaningful advance for patients with germline BRCA1/2 mutations but much more research must be conducted to optimize their use.

Addition of Alpelisib Prolongs PFS in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer Subgroups

March 9th 2019

The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

CDK4/6 Inhibitors Play a Growing Role in Enhancing Endocrine Therapy

March 9th 2019

For more than 100 years, endocrine therapy has been used for the treatment of breast cancer; since that time, we have learned much about the role of estrogen in the biology of normal breast cancer development.

Treatment Tailoring Possible With Gene Expression Profiling

March 9th 2019

Each gene expression-based test available for risk prediction in patients with breast cancer has unique properties and they are not interchangeable, placing importance on the clinical studies used to validate the clinical utility of each assay.

Dr. Mittendorf on FDA Approval of Frontline Atezolizumab/Nab-Paclitaxel in PD-L1+ TNBC

March 9th 2019

Elizabeth A. Mittendorf, MD, PhD, director of the Breast Immuno-Oncology Program at Dana-Farber/Brigham and Women's Cancer Center, discusses the frontline approval of atezolizumab in combination with nab-paclitaxel in patients with locally advanced or metastatic PD-L1

Dr. O'Sullivan on Individualized HER2-Targeted Therapy in HER2+ Breast Cancer

March 9th 2019

Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses how HER2-targeted treatment can be more individualized in the treatment of patients with HER2-positive breast cancer.

FDA Approves Atezolizumab Combo for Frontline TNBC

March 8th 2019

The FDA has approved the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Getting It Right in Breast Cancer Means Being More Precise

March 8th 2019

After nearly 30 years as a breast cancer surgeon, Patrick I. Borgen, MD, finds that the most enduring theme in the field is constant change.

Top Developments in Breast Cancer Research Shape the MBCC Agenda

March 8th 2019

The breast cancer field is experiencing rapid advancements in the understanding of disease biology and the development of novel therapeutic strategies for several subtypes, with a clear direction toward personalized or precision medicine.

Intraoperative Shave Technique Proves Effective in Breast-Conserving Surgery

March 8th 2019

Data from the SHAVE and SHAVE2 trials, in terms of long-term outcomes vis-à-vis local recurrence, may lend some insight into the impact of adjuvant therapy on reducing the ramifications of a positive margin.

Practical Treatment Questions Surface in HR-Positive Metastatic Breast Cancer

March 7th 2019

Novel and emerging agents are creating exciting new options for patients with hormone receptor–positive metastatic breast cancer, resulting in the need to consider how best to introduce and sequence these agents into the treatment timeline.

Tumor Marker Trial Aims to Ease "Scanxiety" in Breast Cancer

March 5th 2019

Breast surveillance is essential when determining whether or not therapy is beneficial and to avoid toxicity, usual care for patients with metastatic breast cancer includes monitoring of symptoms and cancer burden.

Dr. Denduluri on Treatment for ER+/HER2- Breast Cancer

March 5th 2019

Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses treatment for patients with estrogen receptor (ER)-positive, HER2-negative breast cancer.

EU Panel Backs Olaparib for BRCA-Mutant Advanced Breast Cancer

March 2nd 2019

The European Medicine Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to olaparib tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer.

Dr. De Censi Discusses the Results of the Phase III TAM-01 Trial in Breast Cancer

March 1st 2019

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the results of the phase III TAM-01 trial in breast cancer.

Dr. Lindeman on Rationale for a Phase Ib Trial of Venetoclax and Tamoxifen in Breast Cancer

March 1st 2019

Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax (Venclexta) combined with tamoxifen in estrogen receptor-positive and BCL-2–positive metastatic breast cancer.

Dr. Goetz on Treatment of Metastatic HR+ Breast Cancer

February 28th 2019

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses the treatment landscape for patients with metastatic hormone receptor–positive breast cancer.

CDK4/6 Inhibitors Carry Consistent Benefit Across HR+/HER2- Breast Cancer Settings

February 27th 2019

Joseph F. Stilwill, MD, shares insight on the clinical benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlights ongoing research aimed at overcoming acquired resistance.

Dr. Meisel on Emerging Treatment Strategies in TNBC

February 27th 2019

Jane L. Meisel, MD, an assistant professor in the Department of Gynecology & Obstetrics at Emory School of Medicine, Winship Cancer Institute, discusses emerging treatment strategies in triple-negative breast cancer (TNBC).